Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114894 · ClinicalTrials.gov registry record · Phase 3
Prevention of Jellyfish Stings
A Phase 3 study of Bites and Stings, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00114894: Completed Phase 3 study of Bites and Stings, sponsored by University of Minnesota.
NCT00114894 is a Phase 3 study of Bites and Stings that has completed, run by University of Minnesota. The registered enrollment target is 12 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00114894, a Phase 3 study of Bites and Stings, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Jellyfish stings are a common occurrence among ocean-goers worldwide with an estimated 150 million envenomations annually. Fatalities and hospitalizations occur annually, particularly in the Indo-Pacific regions. A new topical jellyfish sting inhibitor based on the mucous coating of the clown fish prevents 85% of jellyfish stings in laboratory settings. The field effectiveness is unknown. This is a field test to determine the real world effectiveness.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Safe Sea ™
Study Locations (1)
Florida
- Dry Tortugas National Park - Key West
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
What the finished NCT00114894 record still lists
NCT00114894 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Bites and Stings appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00114894 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00114894 about?
NCT00114894 is a clinical study titled "Prevention of Jellyfish Stings". Jellyfish stings are a common occurrence among ocean-goers worldwide with an estimated 150 million envenomations annually. Fatalities and hospitalizations occur annually, particularly in the Indo-Pacific regions. A new topical jellyfish sting inhibitor based on the mucous coating of the clown fish p...
What is the current status of trial NCT00114894?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2004-04. Estimated completion is 2006-02.
What conditions does trial NCT00114894 study?
This clinical trial studies the following conditions: Bites and Stings.
What interventions are being tested in trial NCT00114894?
The interventions under investigation include: Placebo (OTHER), Safe Sea ™ (OTHER).
Who is sponsoring clinical trial NCT00114894?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114894 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00114894's enrollment target sits among peer trials
12 1984th of 2000 higher than 12 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia